The purpose of this study was to estabilish the criteria for selecting drugs that were exempted from drug adverse reaction relief system. First, we examined the current state of our system ? How did they selected the drugs that are now exempted from r...
The purpose of this study was to estabilish the criteria for selecting drugs that were exempted from drug adverse reaction relief system. First, we examined the current state of our system ? How did they selected the drugs that are now exempted from relief- and found that we benchmarked similar systems of other countries. Thus, we searched the systems of other countries such as Japan and Taiwan where the drug adverse reaction relief system was similar to ours. We visited pharmaceuticals and medical devices agency (PMDA) in Japan and Taiwan Drug Relief Foundation (TDRF) and discussed much about the relief system and drugs that were exempted from relief. To make an reasonable criteria for exemption, the researches of this study discussed much with each other and other specialists of many areas. Finally we made a criteria for exemption from relief. The criteria was as below. 1. Anticancer drugs and Immunosuppresant drugs after organ/hematopoeitic stem cell transplantation. 2. Had be reported to show severe adverse reactions with high frequency. The definition of ‘severe adverse reaction’ was that adverse reactions that resulted in death, disability or hospitalization. ‘High frequency’ was defined as more than 10% during pre-approval trials. To reflect the decision for exemption timely, we suggest that the decision should be made when the new drug got approval for marketing. We hope the conclusion of this study would help the drug adverse reaction relief system in Korea in the future.